Medical research device company Empatica reported on Tuesday the receipt of the 510(k) clearance from the US Food and Drug Administration (FDA) for Embrace for use in paediatric patients with epilepsy.
Empatica added that Embrace is an epilepsy smartband that detects patterns in motion and physiological signals that may be associated with generalised tonic-clonic seizures and immediately alerts caregivers. It is the US FDA's first non-EEG based physiology signal seizure monitoring system for paediatric use.
Based on the data from the clinical testing in an Epilepsy Monitoring Unit (EMU) among 141 patients diagnosed with epilepsy, about 80 of them were paediatric patients and 61 were adults. About 53 out of 54 generalised tonic-clonic seizures were detected by Embrace for an accuracy rate of 98% during the clinical testing, with the overall FAR for adults being 0.67 and the one for paediatrics being 1.35.
In April 2017, Embrace was CE certified in Europe as a medical device for seizure detection. Embrace has been listed as one of the 18 things that made the world a better place in 2018 by WIRED.
About 25% of all people with epilepsy have generalised tonic-clonic seizures, which are most commonly associated with SUDEP (Sudden Unexpected Death in Epilepsy).
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial